Next Article in Journal
Prevalence of Parent-Reported Food Allergies Among Children in Saudi Arabia
Next Article in Special Issue
Time-Restricted Eating Benefits on Pulmonary Function and Postural Balance in Overweight or Obese Women
Previous Article in Journal
Genetically Determined Circulating Saturated and Unsaturated Fatty Acids and the Occurrence and Exacerbation of Chronic Obstructive Pulmonary Disease—A Two-Sample Mendelian Randomization Study
Previous Article in Special Issue
Long-Term Fasting-Induced Ketosis in 1610 Subjects: Metabolic Regulation and Safety
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review

by
Sthembiso Msane
,
Andile Khathi
* and
Aubrey Sosibo
*
Department of Human Physiology, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa
*
Authors to whom correspondence should be addressed.
Nutrients 2024, 16(16), 2692; https://doi.org/10.3390/nu16162692
Submission received: 14 June 2024 / Revised: 22 July 2024 / Accepted: 12 August 2024 / Published: 14 August 2024
(This article belongs to the Special Issue Intermittent Fasting on Human Health and Disease)

Abstract

:
Intermittent fasting has drawn significant interest in the clinical research community due to its potential to address metabolic complications such as obesity and type 2 diabetes mellitus. Various intermittent fasting regimens include alternate-day fasting (24 h of fasting followed by 24 h of eating), time-restricted fasting (fasting for 14 h and eating within a 10 h window), and the 5:2 diet (fasting for two days and eating normally for the other five days). Intermittent fasting is associated with a reduced risk of type 2 diabetes mellitus-related complications and can slow their progression. The increasing global prevalence of type 2 diabetes mellitus highlights the importance of early management. Since prediabetes is a precursor to type 2 diabetes mellitus, understanding its progression is essential. However, the long-term effects of intermittent fasting on prediabetes are not yet well understood. Therefore, this review aims to comprehensively compile existing knowledge on the therapeutic effects of intermittent fasting in managing type 2 diabetes mellitus and prediabetes.

1. Introduction

Intermittent fasting (IF) is a broad term describing several eating regimens in which individuals alternate long periods of normal calorie intake with periods of minimal or no energy intake [1]. In 1935, McCay elucidated the correlation between calorie restriction and lifespan or longevity [2]. Since then, studies have extensively investigated calorie restriction, evolving into the practice of intermittent fasting [1,3,4,5]. Research findings have highlighted the use of intermittent fasting and its efficacy in metabolic-related disorders [1,3,4,5,6]. Several intermittent fasting protocols have been recognized for their capacity to mitigate metabolic disorders [7,8,9,10,11,12,13,14,15].
The IF protocols include dietary approaches that involve alternating eating periods with either fasting by restricting calorie intake or zero calorie intake during the fasting period [6]. The timing of fasting and feeding periods varies among different IF protocols, such as the 5:2 diet, alternate-day fasting, and time-restricted feeding [16]. The 5:2 fasting diet is a dietary regimen where individuals eat without restrictions for five days, followed by two days per week during which they consume a very-low-calorie diet (fewer than 800 calories per day) [17]. Alternate day fasting (ADF) involves alternating between a 24 h fasting period, during which individuals consume less than 25% of their usual energy needs, and a 24 h eating period, where they can eat normally [15]. Time-restricted feeding (TRF) is an IF protocol with a specified time of prolonged fasting practiced by adhering to 16 h of abstinence from food and 8 h of food intake within 24 h [6]. IF has gained popularity in body weight management and alleviating metabolic-related disorders [18,19]. Therefore, this review aims to synthesize existing knowledge on the therapeutic effects of intermittent fasting on the management of T2DM and prediabetes, providing a critical overview of its current state of understanding. This review will begin by examining the impact of various intermittent fasting protocols on general metabolic issues, particularly those associated with type 2 diabetes (T2DM). Given that T2DM is often preceded by prediabetes, both metabolic states will be discussed. The effects and limitations of conventional management strategies for T2DM and prediabetes will be briefly described. Subsequently, this review will explore the impact of all intermittent fasting regimens on T2DM and prediabetes. Then, future recommendations and conclusions about the possible use of IF regimens in diabetes management will be made.

2. Effects of IF on Metabolic Complications

Obesity has emerged as a notable issue. For example, a study reported an obesity-related death rate of 62,000 out of every 100,000 individuals in the population [20]. Epidemiological studies utilize Body Mass Index (BMI) as a tool to identify individuals who are either obese or overweight [21,22]. Obesity has been correlated with the development of several physiological disorders, including type 2 diabetes, inflammation, cardiovascular disease, hypertension, dyslipidemia, non-alcohol fatty liver disease, and insulin resistance [21,22]. Energy imbalance, leading to excess body fat (≥20%), defines obesity [23,24,25]. Therapeutic interventions such as fasting and the use of antidiabetic medications have been linked to substantial weight loss, suggesting improvements in clinical factors associated with metabolic complications [26,27,28,29].
The fasting regimens mentioned have demonstrated efficacy in eliciting favorable metabolic alterations. The changes include improved glucose control, reduced glycogen storage, release of fatty acids and ketones, decreased levels of leptin, and increased levels of adiponectin [1,30,31,32]. In overweight or obese adults, IF has reported a decrease in BMI, body weight, waist circumference, and fat mass [3,17,33,34,35]. Interestingly, a study conducted in obese middle-aged female Wistar rats found that ADF and TRF did not lead to reductions in blood lipid profiles, adiposity, or insulin resistance. Instead, these dietary interventions increased inflammatory biomarkers, potentially elevating the risk of obesity-associated comorbidities [36]. Other studies reported different outcomes of insulin resistance, blood lipids, adiposity, inflammatory markers, and glycemic control upon IF adherence [37,38].
Insulin resistance (IR) occurs when the main target tissues for insulin action in glucose metabolism do not respond to insulin as they should due to chronic energy surpluses [39]. Therefore, weight loss is essential for regulating disordered glucose and lipid metabolism, notably insulin resistance and hyperinsulinemia caused by central obesity [30,31,40]. Furthermore, insulin resistance has been implicated in T2DM [41,42]. T2DM is a chronic hyperglycaemic condition triggered by a preceding loss of β-cell insulin secretion and insulin resistance [43]. The onset of a metabolic switch brought on by fasting is due to the negative energy balance caused by the depletion of glycogen stores and metabolized fatty acids.
The metabolic switch from using glucose to fatty acid-derived ketones represents a gradual change in the metabolism from lipid/cholesterol synthesis and fat storage to fat mobilization through fatty acid oxidation and fatty acid-derived ketones. As a result, the metabolic switch aids in maintaining muscle mass and its function, which promotes weight loss [16]. During fasting, ketones continuously increase while glucose decreases, and this is inverse to the postprandial state, where glucose levels increase while ketones diminish [44]. The outcomes of the metabolic transition observed during fasting may ameliorate insulin sensitivity and glycaemic regulation detected in persons with non-insulin-dependent diabetes.

3. Type 2 Diabetes Mellitus

Diabetes continues to be a significant contributor to mortality and morbidity rates globally [45]. It is expected that 578 million people will have diabetes by 2030, increasing by 51% (700 million) by 2045 from 463 million in 2019 [45,46]. Approximately 90% to 95% of all diabetes diagnoses are classified as type 2 diabetes mellitus [47]. According to both the American Diabetes Association (ADA) and World Health Organisation (WHO), diabetes can be diagnosed if a person has a fasting plasma glucose level of ≥126 mg/dL (7.0 mmol/L) after fasting for at least 8 h and a plasma glucose level of ≥200 mg/dL (11.1 mmol/L) during a 75 g oral glucose tolerance test (OGTT) [48]. The ADA also uses a glycated hemoglobin (HbA1c) level of at least 6.5% (48 mmol/mol Hb) to diagnose diabetes [49,50]. Both the ADA and the WHO approve diagnosing glucose in plasma, although it can also be measured in serum and whole blood [51,52].
Multiple organs are involved in the pathophysiology of T2DM. Disruption in the pathways connecting the endocrine pancreas, liver, skeletal muscles, and adipose tissues can disrupt glucose regulation, leading to the onset of T2DM, as illustrated in Figure 1. The primary causes of the disruption include chronic inflammatory markers (e.g., Interleukin-6 and C-reactive protein) and overnutrition, especially through diets high in carbohydrates and saturated fats [53]. They disrupt the insulin signaling pathway in muscle, liver, and adipose tissues, resulting in hyperglycemia. Progressive hyperglycemia further damages the β-cells of pancreatic islets by inducing oxidative stress within the β-cells of pancreatic islets [54].

4. Conventional Management of T2DM

4.1. Insulin Therapy

Insulin therapy serves as an injectable medication for diabetes mellitus [55]. The use of exogenous insulin is primarily employed to regulate blood glucose levels and alleviate symptoms of T2DM by replenishing or complementing the body’s natural insulin production from the pancreas [55,56]. Insulin therapy directly activates the insulin receptor, leading to increased glucose uptake, decreased production of glucose by the liver, and decreased breakdown of fats [57]. Hence, insulin therapy is positively associated with a decrease in fasting glucose levels, glucose tolerance, and HbA1c [58,59,60]. Nevertheless, diminishing fat breakdown may lead to the buildup of triglycerides in both the bloodstream and fatty tissues, resulting in an elevated likelihood of gaining weight [61]. The weight gain mechanism in insulin-treated T2DM involves factors such as hypoglycemia-associated snacking, inhibited glucose excretion (glycosuria), and decreased metabolic rates [62].

4.2. Glucagon-like Peptide-1 Receptor Agonists

Glucagon-like peptide-1 (GLP-1) is a hormone primarily located in the gastrointestinal tract, secreted in response to the ingestion of nutrients (carbohydrates and fats) [63]. GLP-1Ra functions by controlling elevated blood glucose levels after meals by increasing the release of insulin from the beta cells [64]. These drugs have been associated with decreased FG, HbA1c, and GT [65,66,67]. Additional benefits encompass suppressing glucagon release, delaying stomach emptying, promoting insulin release, and reducing appetite [63,64,68]. The disadvantages of using GLP-1Ra have been associated not only with gastrointestinal effects but also with gallbladder diseases, attributed to reduced gallbladder refilling [69,70].

4.3. Dipeptidyl Peptidase-4 Inhibitors

Dipeptidyl peptidase-4 inhibitors (DPP4i) function by inhibiting the activity of DPP-4 [71]. DPP4i enhances insulin secretion from pancreatic beta cells in a glucose-dependent manner through the action of GLP-1 while concurrently decreasing glucagon release from alpha cells [68,72]. DPP-4 inhibitors have been demonstrated to effectively lower FG, postprandial glucose, and HbA1c levels while maintaining a low risk of hypoglycemia [72,73]. Nonetheless, there has been a noted rise in the occurrence of acute pancreatitis linked to their utilization [71,74].

4.4. Sodium-Glucose Co-Transport 2 Inhibitors

Sodium-glucose co-transport (SGLT)-2 is a kidney transporter responsible for the reabsorption of glucose from the renal filtrate, thus hindering the excretion of glucose through urine [75]. SGLT2 inhibitors represent a newer class of antihyperglycemic medications that function independently of insulin, providing effects beyond simply lowering glucose levels. These drugs promote urinary glucose excretion and natriuresis by inhibiting the reabsorption of glucose and sodium in the proximal tubule of the kidney [75]. This class of antidiabetic drugs has been revealed to reduce HbA1c levels (~0.51–1.01%), FG, and postprandial glucose [76,77,78]. The disadvantages related to the administration of SGLT2i include increased risk of urinary tract infection, genital infection, and lower limb amputation [79,80].

4.5. Biguanide (Metformin)

Metformin, a commonly prescribed antidiabetic drug, is widely acknowledged as a biguanide with properties that enhance insulin sensitivity [81]. Metformin improves glucose utilization and sensitivity to insulin in tissues outside the liver [82]. At therapeutic doses, metformin utilizes multiple mechanisms to reduce blood glucose levels [83]. This antidiabetic drug has been reported to improve GT, HbA1c, and FG [83]. While the liver is the main target organ for metformin action, there is also evidence suggesting involvement of the intestines [84].
Metformin’s effects in the gastrointestinal tract encompass increased intestinal absorption and lactate generation, elevated concentrations of GLP-1, and modification of bile acid pools, consequently impacting the microbiome’s composition [84]. However, the use of metformin has been associated with the occurrence of vitamin B12 deficiency, which may contribute to the manifestation of diabetic neuropathy symptoms [81,85]. Furthermore, changes in gut flora, alterations in gut motility, competitive inhibition of absorption, and impairment of calcium-dependent membrane actions in the terminal ileum have been proposed as mechanisms contributing to the development of vitamin B12 deficiency associated with metformin use [85,86]. Regular monitoring of vitamin B12 levels and appropriate supplementation may be necessary for individuals on long-term metformin therapy to address this potential concern. Different types of antidiabetic drugs and their mode of action are shown in Table 1.

5. Lifestyle Intervention

Lifestyle intervention is widely recognized for its effectiveness in reducing the risks associated with T2DM [87]. Lifestyle intervention has been linked to reduced occurrences of T2DM and lower incidences of cardiovascular events, microvascular complications, cardiovascular mortality, and all-cause mortality, leading to increased life expectancy in patients with IGT [87]. The application of lifestyle intervention has also been reported as cost-effective for patients who adhere to it [88]. A DPP 10-year follow-up diabetes study showed that at 2.8 years, there was a 58% reduction in the incidence of diabetes among high-risk adults with lifestyle intervention, which was superior to the 31% reduction observed with metformin [89]. In the initial year visit, a mean weight loss of 7 kg was observed [89]. This confirms the superiority of lifestyle intervention over the established first-line drug, metformin. Intervention strategies encompass physical activity, exercise, and dietary plans [90].

5.1. Dietary Intervention

Dietary intervention encompasses the banting diet, the ketogenic diet, and the Mediterranean diet [91,92,93]. The Banting diet is characterized by high protein intake, whereas the ketogenic diet focuses on low carbohydrates, high fat, and adequate protein, and the Mediterranean diet emphasizes a higher consumption of vegetables [91,93,94]. To achieve long-term weight loss, factors such as meal timing and macronutrient composition must counteract compensatory changes in hunger, cravings, and ghrelin suppression mechanisms. These factors can serve as a boost for weight gain after a previous loss [95]. However, dietary intervention has been linked with positive effects on FG, GT, and HbA1c [96,97,98]. Abstinence from food or fasting entails the breakdown of lipids, carbohydrates, and proteins to regulate plasma glucose within the normal range. Progressive accumulation of fats in the pancreas and liver may lead to dysfunction of beta cells, resulting in hyperglycemia. This condition can be reversed by reducing fats in the liver and pancreas [5].

5.2. Increased Physical Activity

Physical activity has demonstrated antidiabetic effects in individuals with T2DM [99]. Physical activity consists of body movements driven by the contraction of skeletal muscles, resulting in increased energy expenditure [99]. Increased physical activity, such as exercise interventions, has been implemented to alleviate hyperglycemia [100]. Research has shown that low- and moderate-intensity exercise can lower FG, GT, and HbA1c levels [101,102]. Qualitative research revealed that obstacles to physical activity can include health issues (such as breathing problems), difficulties with time and lifestyle management (such as lack of time and motivation), and various environmental, social, and cultural factors [103].

6. Effect of Intermittent Fasting on T2DM

6.1. Alternate Day Fasting

Many investigations have been carried out to assess the safety and tolerability of alternate-day fasting regimens, showing promising clinical outcomes related to T2DM [104,105,106]. Research findings suggest that alternate-day fasting can serve as an alternative approach to continuous CR, with superior effects observed in the retention of lean mass [105,107]. The utilization of alternate-day fasting resulted in a significant decrease in total cholesterol and serum triglycerides [108]. Another study, supported by evidence, demonstrated that adherence to alternate-day fasting can positively impact glucose tolerance within 3 weeks via heightened expression of the SIRT1 gene [109]. Despite a notable reduction in total intra-abdominal fat mass, the alternate-day fasting group reported a failure to alleviate diet-induced muscle insulin resistance caused by a high-fat diet [110].
The potential cause may be attributed to a decrease in the expression of GLUT-4 protein in both high-fat ad libitum (HF-AL) and high-fat alternate-day fasting (HF-ADF) rats compared to the Chow group [110]. Conversely, another study showed a positive impact on glycemic control in genetically obese mice undergoing alternate-day fasting despite the absence of significant weight loss [111]. In mice, fructose-induced resistance was alleviated by a 100% restriction on chow food but allowing ad libitum access to a fructose drink during the fasting days of alternate day fasting. This group exhibited significant improvements in insulin sensitivity compared to the control group [112]. A study revealed a direct correlation between alterations in body weight and improvements in glycemic control, insulin sensitivity, and insulin secretion in obese males with and without T2DM [113]. Alternate-day fasting produces superior outcomes, specifically a decrease in fasting insulin levels and insulin resistance, compared to continuous CR in individuals with insulin resistance [34].
Alternate fasting has also been associated with adverse effects, including hunger, impaired cognitive function, and irritability, which may diminish within a month of adherence [114,115]. On the contrary, a six-month study found that combining ADF with a low-carbohydrate diet did not result in changes in appetite [116]. This suggests that various alternate-day fasting protocols may lead to diverse outcomes upon adherence. Therefore, further research is necessary to assess the impact of different alternate-day fasting approaches on the body’s physiological functions.

6.2. The 5:2 Fasting Diet

The 5:2 diet regimen may serve as an alternative approach to continuous CR, exhibiting reported comparable efficacy in weight management and glycemic control [117]. A (600 kcal)/day diet has been demonstrated to yield significant improvements in beta cell function and hepatic insulin sensitivity, potentially leading to a reversal of T2DM [118]. A 12-week study comparing consecutive versus non-consecutive fasting days utilizing the 5:2 diet regimen demonstrated significant reductions in weight and glycemic levels among individuals with T2DM [119]. Dietary restriction of energy intake was associated with substantial improvements in various markers, including reductions in HbA1c levels, improved results in OGTT, decreased pancreatic and liver triacylglycerol stores, and lowered FG levels [118]. However, cautious measures may be necessary for continuous VLCD regimens, particularly in managing oral hypoglycemic agents to prevent hypoglycemia [120]. Additionally, VLCDs can pose long-term risks of complications such as micronutrient deficiencies [121]. The 5:2 diet has been associated with significantly lower compliance rates. It has been indicated that this diet often results in significant overcompensation during non-fasting days [4].

6.3. Time-Restricted Feeding

TRF has been documented to exhibit a high adherence rate among participants [122]. This regimen has been shown to positively influence fasting glucose, glucose tolerance, and HbA1c levels in T2DM [123]. The glycemic impacts can be achieved through the Circadian Timing System [124]. Several studies have proven that aligning with the circadian timing system plays a role in positive outcomes upon TRF adherence [125,126,127,128]. Research involving both humans and animals suggests that early TRF is favored as the superior regimen over late TRF [125,128]. Early TRF has been shown to enhance insulin sensitivity, promote weight loss and fat oxidation, and help manage glycemic levels [128]. Different types of intermittent fasting regimens are shown in Table 2.

7. Prediabetes

Despite the possibility of correcting prediabetes to normal glucose regulation, it nonetheless imposes a strain [134]. Prediabetes can be characterized by elevated blood glucose levels that do not meet the diagnostic criteria for diabetes [135]. Prediabetes has an asymptomatic characteristic, and this makes it hard to diagnose [136]. The prevalence of prediabetes is increasing year after year, with 5% to 10% of prediabetic people advancing to fatal T2DM and its related complications [31,136,137]. The diagnostic criteria of prediabetes include FG, IGT, and HbA1c. However, the WHO does not recognize HbA1c as a diagnostic criterion for prediabetes. It has been shown that the ADA identifies individuals with an IFG of 5.6–6.9 mmol/L, an IGT of 7.8–11.0 mmol/L, and a HbA1c of 5.7–6.4% as prediabetic [138]. The rising prevalence of prediabetes is causing significant concern. Recent research suggests that the global prevalence of prediabetes is expected to exceed 400 million individuals by 2045 [139].
Research has demonstrated that insulin resistance in adipose tissue contributes to the onset of hyperglycemia and associated complications [140,141,142,143]. Insulin resistance in adipose tissue stimulates the increased release of free fatty acids into the bloodstream, facilitating ectopic fat storage [141]. This process induces insulin resistance in the liver and skeletal muscles, culminating in metabolic issues such as elevated glycemic levels, abnormal lipid levels, hypertension, metabolic syndrome, and NAFLD [140,141,142]. Decreased physical fitness has been linked to increased levels of free fatty acids, reduced insulin clearance, diminished insulin sensitivity in muscles, slightly elevated triglycerides, and decreased levels of HDL cholesterol [142]. Additionally, research indicates that prediabetic individuals with insulin resistance face double the risk of cardiovascular disease compared to prediabetic individuals who do not have insulin resistance [144]. Prompt detection of prediabetes and its associated complications is vital for mitigating the risks it poses to individuals.

HOMA-IR

The Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) represents a diagnostic tool used in clinical settings to evaluate the resistance of insulin, calculated as HOMA-IR = (Fasting Insulin (mU/L) × Fasting Glucose (mmol/L))/22.5 [145]. Prediabetic individuals have insulin resistance in their hepatocytes, fatty tissues, or skeletal muscles [146].

8. Prediabetes Management

Irrespective of the current criteria employed for prediabetes diagnosis, the presence of IR, obesity, and either IFG, IGT, or both, still poses the risk of progressing to T2DM [21,22,144,147]. Various measures have been utilized to decrease prediabetes prevalence and progression to T2DM. Primary treatments for prediabetes include a combination of lifestyle changes such as weight loss and increased physical activity, as well as the use of medications such as metformin [148]. Lifestyle changes have demonstrated effectiveness in reducing the risk of developing T2DM, even with less intensive interventions [149].

8.1. Biguanides (Metformin)

Metformin is a medication used for managing both prediabetes and T2DM [83]. Interestingly, research indicates that metformin has beneficial effects on glucose measures such as FG, GT, and HbA1c levels [150,151]. However, using metformin alone is less effective than combining it with other antidiabetic medications or lifestyle changes [151,152]. Furthermore, metformin use is associated with adverse effects such as lactic acidosis, vomiting, and diarrhea [150].

8.2. Lifestyle Modification

A lack of physical activity and obesity significantly contribute to the advancement of T2DM [153]. Physical activity involves the body’s movement through the contraction of skeletal muscles, which leads to an elevation in energy expenditure [154]. Increased physical activity, such as exercise interventions, has been implemented to alleviate prediabetes [100]. Exercise interventions have improved IFG, IR, IGT, HbA1c levels, and weight loss. Exercise is associated with muscle insulin sensitivity [155]. An increase in insulin sensitivity is facilitated by the movement of several GLUT4 transporters to the cell membrane in response to a submaximal insulin stimulus [155], thereby promoting glucose tolerance and reducing glucose levels in the bloodstream [100].
However, short exercise interventions have been reported to fail to alter HDL-C levels [156]. A multivariate analysis found that the duration of exercise per session is a key predictor of changes in HDL cholesterol levels [157]. Additionally, the efficacy of exercise intervention in raising HDL-C levels has been associated with lower BMI or higher total cholesterol levels [157,158]. Variations in blood glucose levels could be affected by the type of physical activity engaged in, and specific exercise modalities might not be viable options for individuals who are overweight or obese [159]. Therefore, overweight or obese prediabetic individuals need to prioritize weight loss as a preliminary step to enhance their HDL-C levels.
Weight loss strategies often involve dietary interventions, which typically entail reducing calorie intake to manage body weight and address other clinical factors [160]. Very-low-calorie restriction has been linked to improvements in beta-cell function, leading to the restoration of the first phase of insulin secretion in prediabetic individuals [161]. Studies have reported a reduction in fasting glucose levels and HbA1c, weight loss, increased fasting insulin levels, and improved Homeostatic Model Assessment of Beta-cell Function (HOMA-β) [161,162]. Nevertheless, elevated fasting ghrelin levels have been correlated with an increased risk of weight regain following weight loss [163]. Interestingly, achieving positive metabolic outcomes through intermittent fasting may not necessarily require weight loss [164].

8.3. Intermittent Fasting

8.3.1. Alternate-Day Fasting

Recent research has emphasized the potential of IF as an alternative approach for addressing metabolic factors associated with prediabetes [52,104,164]. The literature has shown the efficacy and safety of ADF, the 5:2 fasting diet, and TRF in managing prediabetes [165,166]. Although Ingersen and colleagues reported a lack of significant changes in insulin sensitivity or secretion, other studies have suggested that ADF has the potential to decrease body weight, lower fasting insulin levels, improve IFG, reduce postprandial hyperglycemia, and decrease levels of HbA1c [34,113,167].

8.3.2. The 5:2 Fasting Diet

The 5:2 fasting diet has demonstrated notable efficacy in diminishing body weight, improving insulin sensitivity, and lowering both IFG and HbA1c over a 12-week intervention period [168]. Despite achieving favorable results, the effectiveness of fasting methods in enhancing metabolic factors might fluctuate depending on the duration of fasting or the specific fasting strategies employed [52,166]. Fernanda et al. revealed that long-term intermittent feeding led to glucose intolerance while maintaining insulin receptor phosphorylation. It significantly increased insulin receptor nitration in both intra-abdominal adipose tissue and muscle, a modification linked to receptor inactivation [169]. Hence, this study aims to highlight the benefits of the IF regimen, which may serve as the standard alternative approach for prediabetes.

8.3.3. Time-Restricted Feeding

A commonly followed approach to TRF involves fasting for 16 h and consuming meals within an 8 h window each day (16/8) [170]. Alternatively, individuals may choose to fast for 14 h and consume meals within a 10 h window daily (14/10), or they may opt for a 20 h fasting period followed by a 4 h window for food consumption (20/4) [132,171]. Clinical studies have been drawn to these approaches due to their effects in regulating T2DM and its associated complications in short-term studies [12,172]. A systematic review revealed that the 16/8 and 14/10 fasting methods exhibit similar efficacy in weight loss [173].
Research has indicated the effectiveness of adhering to a 14/10 fasting regimen in controlling glycemic levels despite it not affecting insulin sensitivity in T2DM [37,174]. TRF has been demonstrated to increase insulin sensitivity, decrease blood glucose levels, reduce fasting insulin, reduce HbA1c levels, and enhance glucose tolerance by stimulating beta-cell responsiveness [12,37,132,164,172]. On the contrary, the literature has examined the effects of adhering to TRF either early or late in the day. The literature has observed that consuming meals late in the day leads to a suppression of resting energy expenditure, reduced fasting carbohydrate oxidation, and impaired glucose tolerance [175,176]. Meal timing plays a role in weight loss therapy, with delayed lunch consumption being associated with less weight loss compared to eating earlier, regardless of adhering to a hypocaloric diet [177]. Research consistently shows that consuming meals earlier in the day (8 a.m. to 7 p.m.) is notably more effective in reducing body weight, fasting glucose levels, and insulin resistance, enhancing insulin response, and decreasing ghrelin levels compared to eating later in the day (12 p.m. to 11 p.m.) [177,178,179]. Thus, early TRF has superior effects on metabolic factors compared to late TRF. Below is Table 3 summarizing the various types of IF regimens and their effects on prediabetes.

9. Conclusions

The available anti-diabetic medications have demonstrated the potential to improve T2DM and prediabetes. However, significant drawbacks have surfaced, creating an opportunity for alternative approaches. Numerous studies have examined the effects of intermittent fasting on T2DM. However, research on the relationship between intermittent fasting and prediabetes is still scarce. Intermittent fasting has been proven beneficial in short-term studies, highlighting its beneficial impacts on metabolic factors. These effects have been investigated in metabolic disorders such as obesity and T2DM. Nevertheless, the precise mechanisms through which IF modulates glycemic levels and its enduring influence on gene expression, such as GLUT 4 and IRS1, remain unclear. Additionally, the impact of intermittent fasting on glycemic markers and identifying an optimal IF regimen for prediabetes management is yet to be fully elucidated. Therefore, there is a need for comprehensive, long-term investigations to assess the role of IF in glycemic regulation and its associated gene expression, including examining key regulators such as GLUT 4 and IRS1.

Author Contributions

Conceptualization, S.M., A.K. and A.S.; writing―original draft preparation, S.M.; writing―review and editing, S.M., A.K. and A.S.; visualization, S.M., A.K. and A.S.; supervision, A.K. and A.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

Intermittent Fasting IF
Alternate-Day FastingADF
Time-Restricted FeedingTRF
Type 2 Diabetes MellitusT2DM
Body Mass IndexBMI
Insulin ResistanceIR
ΒBeta
American Diabetes AssociationADA
World Health OrganizationWHO
Oral Glucose Tolerance TestOGTT
Glycated HemoglobinHbA1c
Fasting GlucoseFG
Glucagon-Like Peptide 1 Receptor AgonistsGLP-1RA
Glucagon-Like Peptide 1GLP-1
Dipeptidyl Peptidase-4 InhibitorsDPP4i
Dipeptidyl Peptidase 4DPP4
Calorie RestrictionCR
Glucose ToleranceGT
Sodium-Glucose Co-Transporter 2SGLT 2
Sodium-Glucose Co-Transporter 2 InhibitorSGLT-2i
Glucose Transporter 4GLUT-4
High Fats Ad LibitumHF-AL
Diabetes Prevention ProgrammeDPP
Impaired Glucose ToleranceIGT
Impaired Fasting GlucoseIFG
High-Fat Alternate-Day Fasting HF-ADF
Very Low-Calorie DietVLCD
High-Density LipoproteinHDL
High-Density Lipoprotein CholesterolHDL-C
Homeostatic Model Assessment of Insulin ResistanceHOMA-IR
Homeostatic Model Assessment of Beta Cell FunctionHOMA-β
Insulin Receptor Substrate 1IRS1
Nonalcoholic Fatty Liver DiseaseNAFLD
Superoxide DismutaseSOD
Hydrogen PeroxideH2O2
SuperoxideO2

Glossary

Intermittent fasting (IF) is a broad term describing several eating regimens in which individuals alternate long periods of normal calorie intake with periods of minimal or no energy intake. Calorie restriction (CR) is a nutritional approach that involves decreasing caloric intake while maintaining adequate nutrition to prevent malnutrition. Metabolic complications refer to various disorders that stem from dysfunctions in the body’s metabolic processes. Type 2 diabetes mellitus is a chronic, hyperglycemic condition triggered by a preceding loss of β-cell insulin secretion and insulin resistance. Glycated hemoglobin (HbA1c) is a type of hemoglobin that becomes chemically bonded to glucose molecules. It serves as a biomarker for assessing long-term blood glucose levels. Hypoglycemia refers to blood glucose levels that are lower than the usual range. Insulin therapy is an antidiabetic injectable drug. Glucagon-like Peptide 1 receptor agonist (GLP-1RA) is an antidiabetic drug used to mimic the action of the natural hormone GLP-1. GLP-1 is a hormone primarily located in the gastrointestinal tract, secreted in response to the ingestion of nutrients. Dipeptidyl peptidase-4 inhibitors (DPP4i) are an antidiabetic drug that works by inhibiting the activity of DPP-4. Dipeptidyl peptidase-4 (DPP4) is an enzyme that plays a role in GLP-1 degradation. Alternate-day fasting involves alternating between a 24 h fasting period, during which individuals consume less than 25% of their usual energy needs, and a 24 h eating period, where they can eat normally. The 5:2 fasting diet is a dietary regimen where individuals eat without restrictions for five days, followed by two days per week during which they consume a very low-calorie diet (less than 800 calories per day). Time-restricted feeding (TRF) is an IF protocol with a specified time of prolonged fasting, practiced by adhering to 16 h of abstinence from food and 8 h of food intake within 24 h.

References

  1. Mattson, M.P.; Longo, V.D.; Harvie, M. Impact of intermittent fasting on health and disease processes. Ageing Res. Rev. 2017, 39, 46–58. [Google Scholar] [CrossRef] [PubMed]
  2. McDonald, R.B.; Ramsey, J.J. Honoring Clive McCay and 75 Years of Calorie Restriction Research. J. Nutr. 2010, 140, 1205–1210. [Google Scholar] [CrossRef] [PubMed]
  3. He, S.; Wang, J.; Zhang, J.; Xu, J. Intermittent Versus Continuous Energy Restriction for Weight Loss and Metabolic Improvement: A Meta-Analysis and Systematic Review. Obesity 2021, 29, 108–115. [Google Scholar] [CrossRef] [PubMed]
  4. Cook, F.; Langdon-Daly, J.; Serpell, L. Compliance of participants undergoing a ‘5-2’ intermittent fasting diet and impact on body weight. Clin. Nutr. ESPEN 2022, 52, 257–261. [Google Scholar] [CrossRef] [PubMed]
  5. Taylor, R. Calorie restriction for long-term remission of type 2 diabetes. Clin. Med. 2019, 19, 37–42. [Google Scholar] [CrossRef] [PubMed]
  6. Rajpal, A.; Ismail-Beigi, F. Intermittent fasting and ‘metabolic switch’: Effects on metabolic syndrome, prediabetes and type 2 diabetes. Diabetes Obes. Metab. 2020, 22, 1496–1510. [Google Scholar] [CrossRef] [PubMed]
  7. Silva, A.I.; Direito, M.; Pinto-Ribeiro, F.; Ludovico, P.; Sampaio-Marques, B. Effects of Intermittent Fasting on Regulation of Metabolic Homeostasis: A Systematic Review and Meta-Analysis in Health and Metabolic-Related Disorders. J. Clin. Med. 2023, 12, 3699. [Google Scholar] [CrossRef] [PubMed]
  8. Kahleova, H.; Belinova, L.; Malinska, H.; Oliyarnyk, O.; Trnovska, J.; Skop, V.; Kazdova, L.; Dezortova, M.; Hajek, M.; Tura, A.; et al. Eating two larger meals a day (breakfast and lunch) is more effective than six smaller meals in a reduced-energy regimen for patients with type 2 diabetes: A randomised crossover study. Diabetologia 2014, 57, 1552–1560. [Google Scholar] [CrossRef] [PubMed]
  9. Ko, J.; Kimita, W.; Skudder-Hill, L.; Li, X.; Priya, S.; Bharmal, S.H.; Cho, J.; Petrov, M.S. Dietary carbohydrate intake and insulin traits in individuals after acute pancreatitis: Effect modification by intra-pancreatic fat deposition. Pancreatology 2021, 21, 353–362. [Google Scholar] [CrossRef]
  10. Niki, A.; Baden, M.Y.; Kato, S.; Mitsushio, K.; Horii, T.; Ozawa, H.; Ishibashi, C.; Fujita, S.; Kimura, T.; Fujita, Y.; et al. Consumption of two meals per day is associated with increased intrapancreatic fat deposition in patients with type 2 diabetes: A retrospective study. BMJ Open Diabetes Res. Care 2022, 10, e002926. [Google Scholar] [CrossRef]
  11. Sami, W.; Ansari, T.; Butt, N.S.; Hamid, M.R.A. Effect of diet on type 2 diabetes mellitus: A review. Int. J. Health Sci. 2017, 11, 65–71. [Google Scholar]
  12. Cienfuegos, S.; McStay, M.; Gabel, K.; Varady, K.A. Time restricted eating for the prevention of type 2 diabetes. J. Physiol. 2022, 600, 1253–1264. [Google Scholar] [CrossRef]
  13. Harvie, M.N.; Pegington, M.; Mattson, M.P.; Frystyk, J.; Dillon, B.; Evans, G.; Cuzick, J.; Jebb, S.A.; Martin, B.; Cutler, R.G.; et al. The effects of intermittent or continuous energy restriction on weight loss and metabolic disease risk markers: A randomized trial in young overweight women. Int. J. Obes. 2011, 35, 714–727. [Google Scholar] [CrossRef] [PubMed]
  14. Das, S.K.; Gilhooly, C.H.; Golden, J.K.; Pittas, A.G.; Fuss, P.J.; Cheatham, R.A.; Tyler, S.; Tsay, M.; McCrory, M.A.; Lichtenstein, A.H.; et al. Long-term effects of 2 energy-restricted diets differing in glycemic load on dietary adherence, body composition, and metabolism in CALERIE: A 1-y randomized controlled trial. Am. J. Clin. Nutr. 2007, 85, 1023–1030. [Google Scholar] [CrossRef] [PubMed]
  15. Varady, K.A.; Hellerstein, M.K. Alternate-day fasting and chronic disease prevention: A review of human and animal trials. Am. J. Clin. Nutr. 2007, 86, 7–13. [Google Scholar] [CrossRef] [PubMed]
  16. Vasim, I.; Majeed, C.N.; DeBoer, M.D. Intermittent Fasting and Metabolic Health. Nutrients 2022, 14, 631. [Google Scholar] [CrossRef] [PubMed]
  17. Hajek, P.; Przulj, D.; Pesola, F.; McRobbie, H.; Peerbux, S.; Phillips-Waller, A.; Bisal, N.; Myers Smith, K. A randomised controlled trial of the 5:2 diet. PLoS ONE 2021, 16, e0258853. [Google Scholar] [CrossRef]
  18. Aoun, A.; Ghanem, C.; Hamod, N.; Sawaya, S. The Safety and Efficacy of Intermittent Fasting for Weight Loss. Nutr. Today 2020, 55, 270–277. [Google Scholar] [CrossRef]
  19. Kunduraci, Y.E.; Ozbek, H. Does the Energy Restriction Intermittent Fasting Diet Alleviate Metabolic Syndrome Biomarkers? A Randomized Controlled Trial. Nutrients 2020, 12, 3213. [Google Scholar] [CrossRef]
  20. Chew, N.W.S.; Ng, C.H.; Tan, D.J.H.; Kong, G.; Lin, C.; Chin, Y.H.; Lim, W.H.; Huang, D.Q.; Quek, J.; Fu, C.E.; et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab. 2023, 35, 414–428.e3. [Google Scholar] [CrossRef]
  21. Chobot, A.; Górowska-Kowolik, K.; Sokołowska, M.; Jarosz-Chobot, P. Obesity and diabetes—Not only a simple link between two epidemics. Diabetes/Metab. Res. Rev. 2018, 34, e3042. [Google Scholar] [CrossRef] [PubMed]
  22. Al-Sulaiti, H.; Diboun, I.; Agha, M.V.; Mohamed, F.F.S.; Atkin, S.; Domling, A.S.; Elrayess, M.A.; Mazloum, N.A. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. J. Transl. Med. 2019, 17, 348. [Google Scholar] [CrossRef] [PubMed]
  23. Jiang, S.Z.; Lu, W.; Zong, X.F.; Ruan, H.Y.; Liu, Y. Obesity and hypertension. Exp. Ther. Med. 2016, 12, 2395–2399. [Google Scholar] [CrossRef] [PubMed]
  24. Chooi, Y.C.; Ding, C.; Magkos, F. The epidemiology of obesity. Metabolism 2019, 92, 6–10. [Google Scholar] [CrossRef] [PubMed]
  25. Pi-Sunyer, F.X. Obesity: Criteria and classification. Proc. Nutr. Soc. 2000, 59, 505–509. [Google Scholar] [CrossRef] [PubMed]
  26. Zubrzycki, A.; Cierpka-Kmiec, K.; Kmiec, Z.; Wronska, A. The role of low-calorie diets and intermittent fasting in the treatment of obesity and type-2 diabetes. J. Physiol. Pharmacol. 2018, 69, 663–683. [Google Scholar] [CrossRef]
  27. Casanova, F.; Gooding, K.M.; Shore, A.C.; Adingupu, D.D.; Mawson, D.; Ball, C.; Anning, C.; Aizawa, K.; Gates, P.E.; Strain, W.D. Weight change and sulfonylurea therapy are related to 3 year change in microvascular function in people with type 2 diabetes. Diabetologia 2020, 63, 1268–1278. [Google Scholar] [CrossRef] [PubMed]
  28. Catenacci, V.A.; Pan, Z.; Ostendorf, D.; Brannon, S.; Gozansky, W.S.; Mattson, M.P.; Martin, B.; MacLean, P.S.; Melanson, E.L.; Troy Donahoo, W. A randomized pilot study comparing zero-calorie alternate-day fasting to daily caloric restriction in adults with obesity. Obesity 2016, 24, 1874–1883. [Google Scholar] [CrossRef] [PubMed]
  29. Chen, Z.; Li, G. Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials. Clin. Drug Investig. 2019, 39, 521–531. [Google Scholar] [CrossRef]
  30. de la Iglesia, R.; Loria-Kohen, V.; Zulet, M.A.; Martinez, J.A.; Reglero, G.; Ramirez de Molina, A. Dietary Strategies Implicated in the Prevention and Treatment of Metabolic Syndrome. Int. J. Mol. Sci. 2016, 17, 1877. [Google Scholar] [CrossRef]
  31. Yuan, X.; Wang, J.; Yang, S.; Gao, M.; Cao, L.; Li, X.; Hong, D.; Tian, S.; Sun, C. Effect of Intermittent Fasting Diet on Glucose and Lipid Metabolism and Insulin Resistance in Patients with Impaired Glucose and Lipid Metabolism: A Systematic Review and Meta-Analysis. Int. J. Endocrinol. 2022, 2022, 6999907. [Google Scholar] [CrossRef]
  32. Swiatkiewicz, I.; Wozniak, A.; Taub, P.R. Time-Restricted Eating and Metabolic Syndrome: Current Status and Future Perspectives. Nutrients 2021, 13, 221. [Google Scholar] [CrossRef] [PubMed]
  33. Cui, Y.; Cai, T.; Zhou, Z.; Mu, Y.; Lu, Y.; Gao, Z.; Wu, J.; Zhang, Y. Health Effects of Alternate-Day Fasting in Adults: A Systematic Review and Meta-Analysis. Front. Nutr. 2020, 7, 586036. [Google Scholar] [CrossRef] [PubMed]
  34. Gabel, K.; Kroeger, C.M.; Trepanowski, J.F.; Hoddy, K.K.; Cienfuegos, S.; Kalam, F.; Varady, K.A. Differential Effects of Alternate-Day Fasting versus Daily Calorie Restriction on Insulin Resistance. Obesity 2019, 27, 1443–1450. [Google Scholar] [CrossRef] [PubMed]
  35. Arciero, P.J.; Poe, M.; Mohr, A.E.; Ives, S.J.; Arciero, A.; Sweazea, K.L.; Gumpricht, E.; Arciero, K.M. Intermittent fasting and protein pacing are superior to caloric restriction for weight and visceral fat loss. Obesity 2023, 31 (Suppl. S1), 139–149. [Google Scholar] [CrossRef] [PubMed]
  36. Bilibio, B.L.E.; Dos Reis, W.R.; Compagnon, L.; de Batista, D.G.; Sulzbacher, L.M.; Pinheiro, J.F.; Ludwig, M.S.; Frizzo, M.N.; Cruzat, V.; Heck, T.G. Effects of alternate-day fasting and time-restricted feeding in obese middle-aged female rats. Nutrition 2023, 116, 112198. [Google Scholar] [CrossRef]
  37. Che, T.; Yan, C.; Tian, D.; Zhang, X.; Liu, X.; Wu, Z. Time-restricted feeding improves blood glucose and insulin sensitivity in overweight patients with type 2 diabetes: A randomised controlled trial. Nutr. Metab. 2021, 18, 88. [Google Scholar] [CrossRef] [PubMed]
  38. Yun, N.; Nah, J.; Lee, M.N.; Wu, D.; Pae, M. Post-Effects of Time-Restricted Feeding against Adipose Tissue Inflammation and Insulin Resistance in Obese Mice. Nutrients 2023, 15, 2617. [Google Scholar] [CrossRef] [PubMed]
  39. Samuel, V.T.; Shulman, G.I. The pathogenesis of insulin resistance: Integrating signaling pathways and substrate flux. J. Clin. Investig. 2016, 126, 12–22. [Google Scholar] [CrossRef]
  40. Despres, J.P.; Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 2006, 444, 881–887. [Google Scholar] [CrossRef]
  41. Laakso, M.; Kuusisto, J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 2014, 10, 293–302. [Google Scholar] [CrossRef] [PubMed]
  42. Derakhshan, A.; Tohidi, M.; Arshi, B.; Khalili, D.; Azizi, F.; Hadaegh, F. Relationship of hyperinsulinaemia, insulin resistance and beta-cell dysfunction with incident diabetes and pre-diabetes: The Tehran Lipid and Glucose Study. Diabet. Med. 2015, 32, 24–32. [Google Scholar] [CrossRef] [PubMed]
  43. Artasensi, A.; Pedretti, A.; Vistoli, G.; Fumagalli, L. Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules 2020, 25, 1987. [Google Scholar] [CrossRef] [PubMed]
  44. Anton, S.D.; Moehl, K.; Donahoo, W.T.; Marosi, K.; Lee, S.A.; Mainous, A.G., 3rd; Leeuwenburgh, C.; Mattson, M.P. Flipping the Metabolic Switch: Understanding and Applying the Health Benefits of Fasting. Obesity 2018, 26, 254–268. [Google Scholar] [CrossRef] [PubMed]
  45. Collaboration NCDRF. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016, 387, 1513–1530. [Google Scholar] [CrossRef]
  46. Saeedi, P.; Petersohn, I.; Salpea, P.; Malanda, B.; Karuranga, S.; Unwin, N.; Colagiuri, S.; Guariguata, L.; Motala, A.A.; Ogurtsova, K.; et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 2019, 157, 107843. [Google Scholar] [CrossRef]
  47. Deshpande, A.D.; Harris-Hayes, M.; Schootman, M. Epidemiology of diabetes and diabetes-related complications. Phys. Ther. 2008, 88, 1254–1264. [Google Scholar] [CrossRef] [PubMed]
  48. van Dieren, S.; Beulens, J.W.; van der Schouw, Y.T.; Grobbee, D.E.; Neal, B. The global burden of diabetes and its complications: An emerging pandemic. Eur. J. Cardiovasc. Prev. Rehabil. 2010, 17 (Suppl. S1), S3–S8. [Google Scholar] [CrossRef] [PubMed]
  49. Reaven, G.M. Compensatory hyperinsulinemia and the development of an atherogenic lipoprotein profile: The price paid to maintain glucose homeostasis in insulin-resistant individuals. Endocrinol. Metab. Clin. N. Am. 2005, 34, 49–62. [Google Scholar] [CrossRef]
  50. Olefsky, J.M.; Farquhar, J.W.; Reaven, G.M. Reappraisal of the role of insulin in hypertriglyceridemia. Am. J. Med. 1974, 57, 551–560. [Google Scholar] [CrossRef]
  51. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010, 33 (Suppl. S1), S62–S69. [Google Scholar] [CrossRef]
  52. Ojo, T.K.; Joshua, O.O.; Ogedegbe, O.J.; Oluwole, O.; Ademidun, A.; Jesuyajolu, D. Role of Intermittent Fasting in the Management of Prediabetes and Type 2 Diabetes Mellitus. Cureus 2022, 14, e28800. [Google Scholar] [CrossRef]
  53. Phosat, C.; Panprathip, P.; Chumpathat, N.; Prangthip, P.; Chantratita, N.; Soonthornworasiri, N.; Puduang, S.; Kwanbunjan, K. Elevated C-reactive protein, interleukin 6, tumor necrosis factor alpha and glycemic load associated with type 2 diabetes mellitus in rural Thais: A cross-sectional study. BMC Endocr. Disord. 2017, 17, 44. [Google Scholar] [CrossRef]
  54. Rehman, K.; Akash, M.S.H. Mechanism of Generation of Oxidative Stress and Pathophysiology of Type 2 Diabetes Mellitus: How Are They Interlinked? J. Cell. Biochem. 2017, 118, 3577–3585. [Google Scholar] [CrossRef]
  55. Shah, R.B.; Patel, M.; Maahs, D.M.; Shah, V.N. Insulin delivery methods: Past, present and future. Int. J. Pharm. Investig. 2016, 6, 1. [Google Scholar] [CrossRef]
  56. Rys, P.; Wojciechowski, P.; Rogoz-Sitek, A.; Niesyczynski, G.; Lis, J.; Syta, A.; Malecki, M.T. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. 2015, 52, 649–662. [Google Scholar] [CrossRef] [PubMed]
  57. Nathan, D.M.; Buse, J.B.; Davidson, M.B.; Ferrannini, E.; Holman, R.R.; Sherwin, R.; Zinman, B. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32, 193–203. [Google Scholar] [CrossRef] [PubMed]
  58. Clissold, R.; Clissold, S. Insulin glargine in the management of diabetes mellitus: An evidence-based assessment of its clinical efficacy and economic value. Core Evid. 2007, 2, 89–110. [Google Scholar] [CrossRef] [PubMed]
  59. Hajos, T.R.; Pouwer, F.; de Grooth, R.; Holleman, F.; Twisk, J.W.; Diamant, M.; Snoek, F.J. Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health-related quality of life. A prospective cohort study in primary care. Diabet. Med. 2011, 28, 1096–1102. [Google Scholar] [CrossRef]
  60. Wang, Z.; Hedrington, M.S.; Gogitidze Joy, N.; Briscoe, V.J.; Richardson, M.A.; Younk, L.; Nicholson, W.; Tate, D.B.; Davis, S.N. Dose-response effects of insulin glargine in type 2 diabetes. Diabetes Care 2010, 33, 1555–1560. [Google Scholar] [CrossRef] [PubMed]
  61. El-Zayat, S.R.; Sibaii, H.; El-Shamy, K.A. Physiological process of fat loss. Bull. Natl. Res. Cent. 2019, 43, 208. [Google Scholar] [CrossRef]
  62. Davies, M.; Khunti, K. Insulin management in overweight or obese type 2 diabetes patients: The role of insulin glargine. Diabetes Obes. Metab. 2008, 10, 42–49. [Google Scholar] [CrossRef] [PubMed]
  63. Lund, A.; Knop, F.K.; Vilsboll, T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: Differences and similarities. Eur. J. Intern. Med. 2014, 25, 407–414. [Google Scholar] [CrossRef] [PubMed]
  64. Baggio, L.L.; Drucker, D.J. Biology of Incretins: GLP-1 and GIP. Gastroenterology 2007, 132, 2131–2157. [Google Scholar] [CrossRef] [PubMed]
  65. Ajabnoor, G.M.A.; Hashim, K.T.; Alzahrani, M.M.; Alsuheili, A.Z.; Alharbi, A.F.; Alhozali, A.M.; Enani, S.; Eldakhakhny, B.; Elsamanoudy, A. The Possible Effect of the Long-Term Use of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) on Hba1c and Lipid Profile in Type 2 Diabetes Mellitus: A Retrospective Study in KAUH, Jeddah, Saudi Arabia. Diseases 2023, 11, 50. [Google Scholar] [CrossRef] [PubMed]
  66. Tofé, S.; Argüelles, I.; Mena, E.; Serra, G.; Codina, M.; Urgeles, J.R.; García, H.; Pereg, V. Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study. Endocrinol. Diabetes Metab. 2019, 2, e00051. [Google Scholar] [CrossRef]
  67. Kaneto, H.; Kimura, T.; Shimoda, M.; Obata, A.; Sanada, J.; Fushimi, Y.; Nakanishi, S.; Mune, T.; Kaku, K. Favorable Effects of GLP-1 Receptor Agonist against Pancreatic β-Cell Glucose Toxicity and the Development of Arteriosclerosis: “The Earlier, the Better” in Therapy with Incretin-Based Medicine. Int. J. Mol. Sci. 2021, 22, 7917. [Google Scholar] [CrossRef]
  68. Lee, S.; Lee, D.Y. Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. Ann. Pediatr. Endocrinol. Metab. 2017, 22, 15–26. [Google Scholar] [CrossRef] [PubMed]
  69. Bettge, K.; Kahle, M.; Abd El Aziz, M.S.; Meier, J.J.; Nauck, M.A. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes. Metab. 2017, 19, 336–347. [Google Scholar] [CrossRef]
  70. Gether, I.M.; Nexoe-Larsen, C.; Knop, F.K. New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs. J. Clin. Endocrinol. Metab. 2019, 104, 2463–2472. [Google Scholar] [CrossRef]
  71. Deacon, C.F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2020, 16, 642–653. [Google Scholar] [CrossRef] [PubMed]
  72. Solis-Herrera, C.; Triplitt, C.; Garduno-Garcia Jde, J.; Adams, J.; DeFronzo, R.A.; Cersosimo, E. Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: A double-tracer study. Diabetes Care 2013, 36, 2756–2762. [Google Scholar] [CrossRef] [PubMed]
  73. Goldstein, B.J.; Feinglos, M.N.; Lunceford, J.K.; Johnson, J.; Williams-Herman, D.E. Effect of Initial Combination Therapy with Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients with Type 2 Diabetes. Diabetes Care 2007, 30, 1979–1987. [Google Scholar] [CrossRef] [PubMed]
  74. Scheen, A.J. Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin. Drug Saf. 2015, 14, 505–524. [Google Scholar] [CrossRef] [PubMed]
  75. Santos, L.L.; Lima, F.J.C.; Sousa-Rodrigues, C.F.; Barbosa, F.T. Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Rev. Assoc. Med. Bras. 2017, 63, 636–641. [Google Scholar] [CrossRef]
  76. Pinto, L.C.; Rados, D.V.; Remonti, L.R.; Kramer, C.K.; Leitao, C.B.; Gross, J.L. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: A systematic review and meta-analysis. Diabetol. Metab. Syndr. 2015, 7, A58. [Google Scholar] [CrossRef]
  77. Colosimo, S.; Tan, G.D.; Petroni, M.L.; Marchesini, G.; Tomlinson, J.W. Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. Nutr. Metab. Cardiovasc. Dis. 2023, 33, 640–648. [Google Scholar] [CrossRef]
  78. Shigiyama, F.; Kumashiro, N.; Miyagi, M.; Ikehara, K.; Kanda, E.; Uchino, H.; Hirose, T. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study. Cardiovasc. Diabetol. 2017, 16, 84. [Google Scholar] [CrossRef]
  79. Satoh, H. Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control. Diabetol. Int. 2018, 9, 212–214. [Google Scholar] [CrossRef]
  80. Gill, H.K.; Kaur, P.; Mahendru, S.; Mithal, A. Adverse Effect Profile and Effectiveness of Sodium Glucose Co-transporter 2 Inhibitors (SGLT2i)—A Prospective Real-world Setting Study. Indian J. Endocrinol. Metab. 2019, 23, 50–55. [Google Scholar] [CrossRef]
  81. Wang, G.S.; Hoyte, C. Review of Biguanide (Metformin) Toxicity. J. Intensive Care Med. 2019, 34, 863–876. [Google Scholar] [CrossRef] [PubMed]
  82. He, L. Metformin and Systemic Metabolism. Trends Pharmacol. Sci. 2020, 41, 868–881. [Google Scholar] [CrossRef] [PubMed]
  83. Horakova, O.; Kroupova, P.; Bardova, K.; Buresova, J.; Janovska, P.; Kopecky, J.; Rossmeisl, M. Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport. Sci. Rep. 2019, 9, 6156. [Google Scholar] [CrossRef] [PubMed]
  84. McCreight, L.J.; Bailey, C.J.; Pearson, E.R. Metformin and the gastrointestinal tract. Diabetologia 2016, 59, 426–435. [Google Scholar] [CrossRef] [PubMed]
  85. Wakeman, M.; Archer, D.T. Metformin and Micronutrient Status in Type 2 Diabetes: Does Polypharmacy Involving Acid-Suppressing Medications Affect Vitamin B12 Levels? Diabetes Metab. Syndr. Obes. 2020, 13, 2093–2108. [Google Scholar] [CrossRef] [PubMed]
  86. Kozyraki, R.; Cases, O. Vitamin B12 absorption: Mammalian physiology and acquired and inherited disorders. Biochimie 2013, 95, 1002–1007. [Google Scholar] [CrossRef] [PubMed]
  87. Gong, Q.; Zhang, P.; Wang, J.; Ma, J.; An, Y.; Chen, Y.; Zhang, B.; Feng, X.; Li, H.; Chen, X.; et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019, 7, 452–461. [Google Scholar] [CrossRef] [PubMed]
  88. The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention. Diabetes Care 2012, 35, 723–730. [CrossRef] [PubMed]
  89. Diabetes Prevention Program Research Group; Knowler, W.C.; Fowler, S.E.; Hamman, R.F.; Christophi, C.A.; Hoffman, H.J.; Brenneman, A.T.; Brown-Friday, J.O.; Goldberg, R.; Venditti, E.; et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009, 374, 1677–1686. [Google Scholar] [CrossRef]
  90. Cardona-Morrell, M.; Rychetnik, L.; Morrell, S.L.; Espinel, P.T.; Bauman, A. Reduction of diabetes risk in routine clinical practice: Are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis. BMC Public Health 2010, 10, 653. [Google Scholar] [CrossRef]
  91. Lean, M.E.J. Banting Memorial Lecture 2021—Banting, banting, banter and bravado: Convictions meet evidence in the scientific process. Diabet. Med. 2021, 38, e14643. [Google Scholar] [CrossRef] [PubMed]
  92. Hartman, A.L.; Vining, E.P.G. Clinical Aspects of the Ketogenic Diet. Epilepsia 2007, 48, 31–42. [Google Scholar] [CrossRef] [PubMed]
  93. Ortega, R. Importance of functional foods in the Mediterranean diet. Public Health Nutr. 2006, 9, 1136–1140. [Google Scholar] [CrossRef]
  94. Kossoff, E.H.; McGrogan, J.R. Worldwide Use of the Ketogenic Diet. Epilepsia 2005, 46, 280–289. [Google Scholar] [CrossRef] [PubMed]
  95. Jakubowicz, D.; Froy, O.; Wainstein, J.; Boaz, M. Meal timing and composition influence ghrelin levels, appetite scores and weight loss maintenance in overweight and obese adults. Steroids 2012, 77, 323–331. [Google Scholar] [CrossRef] [PubMed]
  96. Taylor, R. Banting Memorial Lecture 2012 Reversing the twin cycles of Type 2 diabetes. Diabet. Med. 2013, 30, 267–275. [Google Scholar] [CrossRef]
  97. Yancy, W.S.; Foy, M.; Chalecki, A.M.; Vernon, M.C.; Westman, E.C. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. Nutr. Metab. 2005, 2, 34. [Google Scholar] [CrossRef] [PubMed]
  98. Koloverou, E.; Esposito, K.; Giugliano, D.; Panagiotakos, D. The effect of Mediterranean diet on the development of type 2 diabetes mellitus: A meta-analysis of 10 prospective studies and 136,846 participants. Metabolism 2014, 63, 903–911. [Google Scholar] [CrossRef]
  99. Bao, W.; Tobias, D.K.; Bowers, K.; Chavarro, J.; Vaag, A.; Grunnet, L.G.; Strøm, M.; Mills, J.; Liu, A.; Kiely, M.; et al. Physical Activity and Sedentary Behaviors Associated with Risk of Progression from Gestational Diabetes Mellitus to Type 2 Diabetes Mellitus. JAMA Intern. Med. 2014, 174, 1047. [Google Scholar] [CrossRef]
  100. Hrubeniuk, T.J.; Bouchard, D.R.; Goulet, E.D.B.; Gurd, B.; Sénéchal, M. The ability of exercise to meaningfully improve glucose tolerance in people living with prediabetes: A meta-analysis. Scand. J. Med. Sci. Sports 2020, 30, 209–216. [Google Scholar] [CrossRef]
  101. Agboola, S.; Jethwani, K.; Lopez, L.; Searl, M.; O’Keefe, S.; Kvedar, J. Text to Move: A Randomized Controlled Trial of a Text-Messaging Program to Improve Physical Activity Behaviors in Patients with Type 2 Diabetes Mellitus. J. Med. Internet Res. 2016, 18, e307. [Google Scholar] [CrossRef] [PubMed]
  102. Hansen, D.; Dendale, P.; Jonkers, R.A.M.; Beelen, M.; Manders, R.J.F.; Corluy, L.; Mullens, A.; Berger, J.; Meeusen, R.; Van Loon, L.J.C. Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood HbA1c in obese type 2 diabetes patients. Diabetologia 2009, 52, 1789–1797. [Google Scholar] [CrossRef] [PubMed]
  103. Medagama, A.; Galgomuwa, M. Lack of infrastructure, social and cultural factors limit physical activity among patients with type 2 diabetes in rural Sri Lanka, a qualitative study. PLoS ONE 2018, 13, e0192679. [Google Scholar] [CrossRef] [PubMed]
  104. Trepanowski, J.F.; Kroeger, C.M.; Barnosky, A.; Klempel, M.C.; Bhutani, S.; Hoddy, K.K.; Gabel, K.; Freels, S.; Rigdon, J.; Rood, J.; et al. Effect of Alternate-Day Fasting on Weight Loss, Weight Maintenance, and Cardioprotection Among Metabolically Healthy Obese Adults. JAMA Intern. Med. 2017, 177, 930. [Google Scholar] [CrossRef] [PubMed]
  105. Barnosky, A.R.; Hoddy, K.K.; Unterman, T.G.; Varady, K.A. Intermittent fasting vs daily calorie restriction for type 2 diabetes prevention: A review of human findings. Transl. Res. 2014, 164, 302–311. [Google Scholar] [CrossRef] [PubMed]
  106. Xu, S.; Jiang, Y.; Zhang, Y.; Xu, W.; Zhang, H.; Yan, Q.; Gao, L.; Shang, L. Dietary recommendations for fasting days in an alternate-day intermittent fasting pattern: A randomized controlled trial. Nutrition 2022, 102, 111735. [Google Scholar] [CrossRef] [PubMed]
  107. Varady, K.A. Intermittent versus daily calorie restriction: Which diet regimen is more effective for weight loss? Obes. Rev. 2011, 12, e593–e601. [Google Scholar] [CrossRef] [PubMed]
  108. Cai, H.; Qin, Y.-L.; Shi, Z.-Y.; Chen, J.-H.; Zeng, M.-J.; Zhou, W.; Chen, R.-Q.; Chen, Z.-Y. Effects of alternate-day fasting on body weight and dyslipidaemia in patients with non-alcoholic fatty liver disease: A randomised controlled trial. BMC Gastroenterol. 2019, 19, 219. [Google Scholar] [CrossRef] [PubMed]
  109. Heilbronn, L.K.; Civitarese, A.E.; Bogacka, I.; Smith, S.R.; Hulver, M.; Ravussin, E. Glucose Tolerance and Skeletal Muscle Gene Expression in Response to Alternate Day Fasting. Obes. Res. 2005, 13, 574–581. [Google Scholar] [CrossRef]
  110. Higashida, K.; Fujimoto, E.; Higuchi, M.; Terada, S. Effects of alternate-day fasting on high-fat diet-induced insulin resistance in rat skeletal muscle. Life Sci. 2013, 93, 208–213. [Google Scholar] [CrossRef]
  111. Swoap, S.J.; Bingaman, M.J.; Hult, E.M.; Sandstrom, N.J. Alternate-day feeding leads to improved glucose regulation on fasting days without significant weight loss in genetically obese mice. Am. J. Physiol.-Regul. Integr. Comp. Physiol. 2019, 317, R461–R469. [Google Scholar] [CrossRef] [PubMed]
  112. Beigy, M.; Vakili, S.; Berijani, S.; Aminizade, M.; Ahmadi-Dastgerdi, M.; Meshkani, R. Alternate-day fasting diet improves fructose-induced insulin resistance in mice. J. Anim. Physiol. Anim. Nutr. 2013, 97, 1125–1131. [Google Scholar] [CrossRef] [PubMed]
  113. Ingersen, A.; Helset, H.R.; Calov, M.; Chabanova, E.; Harreskov, E.G.; Jensen, C.; Hansen, C.N.; Prats, C.; Helge, J.W.; Larsen, S.; et al. Metabolic effects of alternate-day fasting in males with obesity with or without type 2 diabetes. Front. Physiol. 2022, 13, 1061063. [Google Scholar] [CrossRef] [PubMed]
  114. De Cabo, R.; Mattson, M.P. Effects of Intermittent Fasting on Health, Aging, and Disease. N. Engl. J. Med. 2019, 381, 2541–2551. [Google Scholar] [CrossRef] [PubMed]
  115. Kroeger, C.M.; Trepanowski, J.F.; Klempel, M.C.; Barnosky, A.; Bhutani, S.; Gabel, K.; Varady, K.A. Eating behavior traits of successful weight losers during 12 months of alternate-day fasting: An exploratory analysis of a randomized controlled trial. Nutr. Health 2018, 24, 5–10. [Google Scholar] [CrossRef] [PubMed]
  116. Kalam, F.; Gabel, K.; Cienfuegos, S.; Wiseman, E.; Ezpeleta, M.; Pavlou, V.; Varady, K.A. Changes in subjective measures of appetite during 6 months of alternate day fasting with a low carbohydrate diet. Clin. Nutr. ESPEN 2021, 41, 417–422. [Google Scholar] [CrossRef] [PubMed]
  117. Carter, S.; Clifton, P.M.; Keogh, J.B. The effects of intermittent compared to continuous energy restriction on glycaemic control in type 2 diabetes; a pragmatic pilot trial. Diabetes Res. Clin. Pract. 2016, 122, 106–112. [Google Scholar] [CrossRef] [PubMed]
  118. Lim, E.L.; Hollingsworth, K.G.; Aribisala, B.S.; Chen, M.J.; Mathers, J.C.; Taylor, R. Reversal of type 2 diabetes: Normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011, 54, 2506–2514. [Google Scholar] [CrossRef] [PubMed]
  119. Corley, B.T.; Carroll, R.W.; Hall, R.M.; Weatherall, M.; Parry-Strong, A.; Krebs, J.D. Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: A randomized controlled trial. Diabet. Med. 2018, 35, 588–594. [Google Scholar] [CrossRef]
  120. Carter, S.; Clifton, P.M.; Keogh, J.B. Intermittent energy restriction in type 2 diabetes: A short discussion of medication management. World J. Diabetes 2016, 7, 627–630. [Google Scholar] [CrossRef]
  121. Baker, S.; Jerums, G.; Proietto, J. Effects and clinical potential of very-low-calorie diets (VLCDs) in type 2 diabetes. Diabetes Res. Clin. Pract. 2009, 85, 235–242. [Google Scholar] [CrossRef] [PubMed]
  122. Wu, B.; White, K.; Maw, M.T.T.; Charleston, J.; Zhao, D.; Guallar, E.; Appel, L.J.; Clark, J.M.; Maruthur, N.M.; Pilla, S.J. Adherence to Diet and Meal Timing in a Randomized Controlled Feeding Study of Time-Restricted Feeding. Nutrients 2022, 14, 2283. [Google Scholar] [CrossRef] [PubMed]
  123. Hutchison, A.T.; Regmi, P.; Manoogian, E.N.C.; Fleischer, J.G.; Wittert, G.A.; Panda, S.; Heilbronn, L.K. Time-Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial. Obesity 2019, 27, 724–732. [Google Scholar] [CrossRef] [PubMed]
  124. de Goede, P.; Foppen, E.; Ritsema, W.; Korpel, N.L.; Yi, C.X.; Kalsbeek, A. Time-Restricted Feeding Improves Glucose Tolerance in Rats, but Only When in Line with the Circadian Timing System. Front. Endocrinol. 2019, 10, 554. [Google Scholar] [CrossRef] [PubMed]
  125. Lynch, S.; Johnston, J.D.; Robertson, M.D. Early versus late time-restricted feeding in adults at increased risk of developing type 2 diabetes: Is there an optimal time to eat for metabolic health? Nutr. Bull. 2021, 46, 69–76. [Google Scholar] [CrossRef]
  126. Lowe, D.A.; Wu, N.; Rohdin-Bibby, L.; Moore, A.H.; Kelly, N.; Liu, Y.E.; Philip, E.; Vittinghoff, E.; Heymsfield, S.B.; Olgin, J.E.; et al. Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men with Overweight and Obesity. JAMA Intern. Med. 2020, 180, 1491. [Google Scholar] [CrossRef] [PubMed]
  127. Parr, E.B.; Devlin, B.L.; Radford, B.E.; Hawley, J.A. A Delayed Morning and Earlier Evening Time-Restricted Feeding Protocol for Improving Glycemic Control and Dietary Adherence in Men with Overweight/Obesity: A Randomized Controlled Trial. Nutrients 2020, 12, 505. [Google Scholar] [CrossRef] [PubMed]
  128. Tsameret, S.; Chapnik, N.; Froy, O. Effect of early vs. late time-restricted high-fat feeding on circadian metabolism and weight loss in obese mice. Cell. Mol. Life Sci. 2023, 80, 180. [Google Scholar] [CrossRef] [PubMed]
  129. Xiao, Y.; Liu, Y.; Zhao, L.; Zhou, Y. Effect of 5:2 Fasting Diet on Liver Fat Content in Patients with Type 2 Diabetic with Nonalcoholic Fatty Liver Disease. Metab. Syndr. Relat. Disord. 2022, 20, 459–465. [Google Scholar] [CrossRef]
  130. Parvaresh, A.; Razavi, R.; Abbasi, B.; Yaghoobloo, K.; Hassanzadeh, A.; Mohammadifard, N.; Safavi, S.M.; Hadi, A.; Clark, C.C.T. Modified alternate-day fasting vs. calorie restriction in the treatment of patients with metabolic syndrome: A randomized clinical trial. Complement. Ther. Med. 2019, 47, 102187. [Google Scholar] [CrossRef]
  131. Sukkriang, N.; Buranapin, S. Effect of intermittent fasting 16:8 and 14:10 compared with control-group on weight reduction and metabolic outcomes in obesity with type 2 diabetes patients: A randomized controlled trial. J. Diabetes Investig. 2024, 31, 92–104.e5. [Google Scholar] [CrossRef] [PubMed]
  132. Wilkinson, M.J.; Manoogian, E.N.C.; Zadourian, A.; Lo, H.; Fakhouri, S.; Shoghi, A.; Wang, X.; Fleischer, J.G.; Navlakha, S.; Panda, S.; et al. Ten-Hour Time-Restricted Eating Reduces Weight, Blood Pressure, and Atherogenic Lipids in Patients with Metabolic Syndrome. Cell Metab. 2020, 31, 92–104. [Google Scholar] [CrossRef] [PubMed]
  133. Antoni, R.; Robertson, T.M.; Robertson, M.D.; Johnston, J.D. A pilot feasibility study exploring the effects of a moderate time-restricted feeding intervention on energy intake, adiposity and metabolic physiology in free-living human subjects. J. Nutr. Sci. 2018, 7, e22. [Google Scholar] [CrossRef]
  134. Perreault, L.; Pan, Q.; Mather, K.J.; Watson, K.E.; Hamman, R.F.; Kahn, S.E.; Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: Results from the Diabetes Prevention Program Outcomes Study. Lancet 2012, 379, 2243–2251. [Google Scholar] [CrossRef] [PubMed]
  135. Abraham, T.M.; Fox, C.S. Implications of rising prediabetes prevalence. Diabetes Care 2013, 36, 2139–2141. [Google Scholar] [CrossRef]
  136. Gong, R.; Liu, Y.; Luo, G.; Liu, W.; Jin, Z.; Xu, Z.; Li, Z.; Yang, L.; Wei, X. Associations of TG/HDL Ratio with the Risk of Prediabetes and Diabetes in Chinese Adults: A Chinese Population Cohort Study Based on Open Data. Int. J. Endocrinol. 2021, 2021, 9949579. [Google Scholar] [CrossRef] [PubMed]
  137. Brannick, B.; Wynn, A.; Dagogo-Jack, S. Prediabetes as a toxic environment for the initiation of microvascular and macrovascular complications. Exp. Biol. Med. 2016, 241, 1323–1331. [Google Scholar] [CrossRef] [PubMed]
  138. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2013, 36, S67–S74. [CrossRef]
  139. Rooney, M.R.; Fang, M.; Ogurtsova, K.; Ozkan, B.; Echouffo-Tcheugui, J.B.; Boyko, E.J.; Magliano, D.J.; Selvin, E. Global Prevalence of Prediabetes. Diabetes Care 2023, 46, 1388–1394. [Google Scholar] [CrossRef]
  140. Lomonaco, R.; Ortiz-Lopez, C.; Orsak, B.; Webb, A.; Hardies, J.; Darland, C.; Finch, J.; Gastaldelli, A.; Harrison, S.; Tio, F.; et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 2012, 55, 1389–1397. [Google Scholar] [CrossRef]
  141. Rattarasarn, C. Dysregulated lipid storage and its relationship with insulin resistance and cardiovascular risk factors in non-obese Asian patients with type 2 diabetes. Adipocyte 2018, 7, 71–80. [Google Scholar] [CrossRef] [PubMed]
  142. Sugimoto, D.; Tamura, Y.; Takeno, K.; Kaga, H.; Someya, Y.; Kakehi, S.; Funayama, T.; Furukawa, Y.; Suzuki, R.; Kadowaki, S.; et al. Clinical Features of Nonobese, Apparently Healthy, Japanese Men with Reduced Adipose Tissue Insulin Sensitivity. J. Clin. Endocrinol. Metab. 2019, 104, 2325–2333. [Google Scholar] [CrossRef] [PubMed]
  143. Kim, J.Y.; Bacha, F.; Tfayli, H.; Michaliszyn, S.F.; Yousuf, S.; Arslanian, S. Adipose Tissue Insulin Resistance in Youth on the Spectrum from Normal Weight to Obese and from Normal Glucose Tolerance to Impaired Glucose Tolerance to Type 2 Diabetes. Diabetes Care 2019, 42, 265–272. [Google Scholar] [CrossRef] [PubMed]
  144. Salazar, M.R.; Carbajal, H.A.; Espeche, W.G.; Aizpurúa, M.; Leiva Sisnieguez, C.E.; Leiva Sisnieguez, B.C.; Stavile, R.N.; March, C.E.; Reaven, G.M. Insulin resistance: The linchpin between prediabetes and cardiovascular disease. Diabetes Vasc. Dis. Res. 2016, 13, 157–163. [Google Scholar] [CrossRef] [PubMed]
  145. Gayoso-Diz, P.; Otero-González, A.; Rodriguez-Alvarez, M.X.; Gude, F.; García, F.; De Francisco, A.; Quintela, A.G. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: Effect of gender and age: EPIRCE cross-sectional study. BMC Endocr. Disord. 2013, 13, 47. [Google Scholar] [CrossRef] [PubMed]
  146. Guemes, M.; Rahman, S.A.; Hussain, K. What is a normal blood glucose? Arch. Dis. Child. 2016, 101, 569–574. [Google Scholar] [CrossRef] [PubMed]
  147. Gerstein, H.C.; Santaguida, P.; Raina, P.; Morrison, K.M.; Balion, C.; Hunt, D.; Yazdi, H.; Booker, L. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: A systematic overview and meta-analysis of prospective studies. Diabetes Res. Clin. Pract. 2007, 78, 305–312. [Google Scholar] [CrossRef]
  148. Echouffo-Tcheugui, J.B.; Perreault, L.; Ji, L.; Dagogo-Jack, S. Diagnosis and Management of Prediabetes: A Review. JAMA 2023, 329, 1206–1216. [Google Scholar] [CrossRef] [PubMed]
  149. Saito, T. Lifestyle Modification and Prevention of Type 2 Diabetes in Overweight Japanese with Impaired Fasting Glucose Levels. Arch. Intern. Med. 2011, 171, 1352. [Google Scholar] [CrossRef]
  150. Reasner, C.; Olansky, L.; Seck, T.L.; Williams-Herman, D.E.; Chen, M.; Terranella, L.; Johnson-Levonas, A.O.; Kaufman, K.D.; Goldstein, B.J. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 2011, 13, 644–652. [Google Scholar] [CrossRef]
  151. Ding, Y.; Liu, Y.; Qu, Y.; Lin, M.; Dong, F.; Li, Y.; Cao, L.; Lin, S. Efficacy and safety of combination therapy with vildagliptin and metformin vs. metformin monotherapy for Type 2 Diabetes Mellitus therapy: A meta-analysis. Eur. Rev. Med. Pharmacol. Sci. 2022, 26, 2802–2817. [Google Scholar] [CrossRef] [PubMed]
  152. Terada, T.; Boule, N.G. Does metformin therapy influence the effects of intensive lifestyle intervention? Exploring the interaction between first line therapies in the Look AHEAD trial. Metabolism 2019, 94, 39–46. [Google Scholar] [CrossRef] [PubMed]
  153. Rana, J.S.; Li, T.Y.; Manson, J.E.; Hu, F.B. Adiposity Compared with Physical Inactivity and Risk of Type 2 Diabetes in Women. Diabetes Care 2007, 30, 53–58. [Google Scholar] [CrossRef]
  154. Hamasaki, H. Daily physical activity and type 2 diabetes: A review. World J. Diabetes 2016, 7, 243–251. [Google Scholar] [CrossRef] [PubMed]
  155. Holloszy, J.O. Exercise-induced increase in muscle insulin sensitivity. J. Appl. Physiol. 2005, 99, 338–343. [Google Scholar] [CrossRef]
  156. Chen, A.K.; Roberts, C.K.; Barnard, R.J. Effect of a short-term diet and exercise intervention on metabolic syndrome in overweight children. Metabolism 2006, 55, 871–878. [Google Scholar] [CrossRef] [PubMed]
  157. Durstine, J.L. Effect of aerobic exercise on high-density lipoprotein cholesterol: A meta-analysis. Clin. J. Sport. Med. 2008, 18, 107–108. [Google Scholar] [CrossRef] [PubMed]
  158. Kodama, S.; Tanaka, S.; Saito, K.; Shu, M.; Sone, Y.; Onitake, F.; Suzuki, E.; Shimano, H.; Yamamoto, S.; Kondo, K.; et al. Effect of aerobic exercise training on serum levels of high-density lipoprotein cholesterol: A meta-analysis. Arch. Intern. Med. 2007, 167, 999–1008. [Google Scholar] [CrossRef] [PubMed]
  159. Janssen, S.M.; Connelly, D.M. The effects of exercise interventions on physical function tests and glycemic control in adults with type 2 diabetes: A systematic review. J. Bodyw. Mov. Ther. 2021, 28, 283–293. [Google Scholar] [CrossRef]
  160. Magkos, F.; Hjorth, M.F.; Astrup, A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 2020, 16, 545–555. [Google Scholar] [CrossRef]
  161. Wei, J.; Chen, J.; Wei, X.; Xiang, X.; Cheng, Q.; Xu, J.; Xu, S.; Chen, G.; Liu, C. Long-term remission of type 2 diabetes after very-low-calorie restriction and related predictors. Front. Endocrinol. 2022, 13, 968239. [Google Scholar] [CrossRef] [PubMed]
  162. McAndrew, L.M.; Napolitano, M.A.; Pogach, L.M.; Quigley, K.S.; Shantz, K.L.; Vander Veur, S.S.; Foster, G.D. The impact of self-monitoring of blood glucose on a behavioral weight loss intervention for patients with type 2 diabetes. Diabetes Educ. 2013, 39, 397–405. [Google Scholar] [CrossRef] [PubMed]
  163. Thom, G.; McIntosh, A.; Messow, C.M.; Leslie, W.S.; Barnes, A.C.; Brosnahan, N.; McCombie, L.; Malkova, D.; Al-Mrabeh, A.; Zhyzhneuskaya, S.; et al. Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT). Diabetes Obes. Metab. 2021, 23, 711–719. [Google Scholar] [CrossRef] [PubMed]
  164. Sutton, E.F.; Beyl, R.; Early, K.S.; Cefalu, W.T.; Ravussin, E.; Peterson, C.M. Early Time-Restricted Feeding Improves Insulin Sensitivity, Blood Pressure, and Oxidative Stress Even without Weight Loss in Men with Prediabetes. Cell Metab. 2018, 27, 1212–1221.e3. [Google Scholar] [CrossRef] [PubMed]
  165. Gao, Y.; Tsintzas, K.; Macdonald, I.A.; Cordon, S.M.; Taylor, M.A. Effects of intermittent (5:2) or continuous energy restriction on basal and postprandial metabolism: A randomised study in normal-weight, young participants. Eur. J. Clin. Nutr. 2022, 76, 65–73. [Google Scholar] [CrossRef] [PubMed]
  166. Chair, S.Y.; Cai, H.; Cao, X.; Qin, Y.; Cheng, H.Y.; Ng, M.T. Intermittent Fasting in Weight Loss and Cardiometabolic Risk Reduction: A Randomized Controlled Trial. J. Nurs. Res. 2022, 30, e185. [Google Scholar] [CrossRef] [PubMed]
  167. Nowosad, K.; Sujka, M. Effect of Various Types of Intermittent Fasting (IF) on Weight Loss and Improvement of Diabetic Parameters in Human. Curr. Nutr. Rep. 2021, 10, 146–154. [Google Scholar] [CrossRef] [PubMed]
  168. Li, M.; Li, J.; Xu, Y.; Gao, J.; Cao, Q.; Ding, Y.; Xin, Z.; Lu, M.; Li, X.; Song, H.; et al. Effect of 5:2 Regimens: Energy-Restricted Diet or Low-Volume High-Intensity Interval Training Combined with Resistance Exercise on Glycemic Control and Cardiometabolic Health in Adults with Overweight/Obesity and Type 2 Diabetes—A Three-Arm Randomized Controlled Trial. Diabetes Care 2024, 47, 1074–1083. [Google Scholar] [CrossRef] [PubMed]
  169. Cerqueira, F.M.; da Cunha, F.M.; Caldeira da Silva, C.C.; Chausse, B.; Romano, R.L.; Garcia, C.C.; Colepicolo, P.; Medeiros, M.H.; Kowaltowski, A.J. Long-term intermittent feeding, but not caloric restriction, leads to redox imbalance, insulin receptor nitration, and glucose intolerance. Free Radic. Biol. Med. 2011, 51, 1454–1460. [Google Scholar] [CrossRef]
  170. Gabel, K.; Hoddy, K.K.; Haggerty, N.; Song, J.; Kroeger, C.M.; Trepanowski, J.F.; Panda, S.; Varady, K.A. Effects of 8-hour time restricted feeding on body weight and metabolic disease risk factors in obese adults: A pilot study. Nutr. Healthy Aging 2018, 4, 345–353. [Google Scholar] [CrossRef]
  171. Tinsley, G.M.; La Bounty, P.M. Effects of intermittent fasting on body composition and clinical health markers in humans. Nutr. Rev. 2015, 73, 661–674. [Google Scholar] [CrossRef] [PubMed]
  172. Martens, C.R.; Rossman, M.J.; Mazzo, M.R.; Jankowski, L.R.; Nagy, E.E.; Denman, B.A.; Richey, J.J.; Johnson, S.A.; Ziemba, B.P.; Wang, Y.; et al. Short-term time-restricted feeding is safe and feasible in non-obese healthy midlife and older adults. GeroScience 2020, 42, 667–686. [Google Scholar] [CrossRef] [PubMed]
  173. Tsitsou, S.; Zacharodimos, N.; Poulia, K.A.; Karatzi, K.; Dimitriadis, G.; Papakonstantinou, E. Effects of Time-Restricted Feeding and Ramadan Fasting on Body Weight, Body Composition, Glucose Responses, and Insulin Resistance: A Systematic Review of Randomized Controlled Trials. Nutrients 2022, 14, 4778. [Google Scholar] [CrossRef] [PubMed]
  174. Andriessen, C.; Fealy, C.E.; Veelen, A.; van Beek, S.M.M.; Roumans, K.H.M.; Connell, N.J.; Mevenkamp, J.; Moonen-Kornips, E.; Havekes, B.; Schrauwen-Hinderling, V.B.; et al. Three weeks of time-restricted eating improves glucose homeostasis in adults with type 2 diabetes but does not improve insulin sensitivity: A randomised crossover trial. Diabetologia 2022, 65, 1710–1720. [Google Scholar] [CrossRef] [PubMed]
  175. Ravussin, E.; Beyl, R.A.; Poggiogalle, E.; Hsia, D.S.; Peterson, C.M. Early Time-Restricted Feeding Reduces Appetite and Increases Fat Oxidation But Does Not Affect Energy Expenditure in Humans. Obesity 2019, 27, 1244–1254. [Google Scholar] [CrossRef] [PubMed]
  176. Bandin, C.; Scheer, F.A.; Luque, A.J.; Avila-Gandia, V.; Zamora, S.; Madrid, J.A.; Gomez-Abellan, P.; Garaulet, M. Meal timing affects glucose tolerance, substrate oxidation and circadian-related variables: A randomized, crossover trial. Int. J. Obes. 2015, 39, 828–833. [Google Scholar] [CrossRef] [PubMed]
  177. Garaulet, M.; Gomez-Abellan, P.; Alburquerque-Bejar, J.J.; Lee, Y.C.; Ordovas, J.M.; Scheer, F.A. Timing of food intake predicts weight loss effectiveness. Int. J. Obes. 2013, 37, 604–611. [Google Scholar] [CrossRef] [PubMed]
  178. Jakubowicz, D.; Barnea, M.; Wainstein, J.; Froy, O. High Caloric intake at breakfast vs. dinner differentially influences weight loss of overweight and obese women. Obesity 2013, 21, 2504–2512. [Google Scholar] [CrossRef]
  179. Allison, K.C.; Hopkins, C.M.; Ruggieri, M.; Spaeth, A.M.; Ahima, R.S.; Zhang, Z.; Taylor, D.M.; Goel, N. Prolonged, Controlled Daytime versus Delayed Eating Impacts Weight and Metabolism. Curr. Biol. 2021, 31, 650–657.e3. [Google Scholar] [CrossRef]
  180. Sundfør, T.M.; Svendsen, M.; Tonstad, S. Effect of intermittent versus continuous energy restriction on weight loss, maintenance and cardiometabolic risk: A randomized 1-year trial. Nutr. Metab. Cardiovasc. Dis. 2018, 28, 698–706. [Google Scholar] [CrossRef]
Figure 1. Illustrates the primary organs and molecules whose modifications contribute to the progression of type 2 diabetes mellitus.
Figure 1. Illustrates the primary organs and molecules whose modifications contribute to the progression of type 2 diabetes mellitus.
Nutrients 16 02692 g001
Table 1. Shows the different types of antidiabetic drugs and their mode of action, effects on glucose parameters, and shortfalls.
Table 1. Shows the different types of antidiabetic drugs and their mode of action, effects on glucose parameters, and shortfalls.
Types of Antidiabetic Drug(s)Mode of ActionEffects on Glucose ParametersShortfall(s)
Insulin therapyDirect glucose-lowering effect.
Facilitation of glucose uptake by cells.
Inhibition of hepatic glucose production.
Promotion of glycogen synthesis.
Reduced FG,
Reduced GT
Reduced HbA1c
Weight gain
GLP-1RASlowing of gastric emptying
Suppression of glucagon secretion
Enhancement of glucose-dependent insulin secretion
Improvement in Beta Cell Function
Reduction of Appetite and Food Intake
Reduced FG,
Reduced GT
Reduced HbA1c
Gastrointestinal effects
Gallbladder disease
DPP4iInhibition of DPP-4 enzyme
Reduction in Blood Glucose Levels
Prolongation of incretin hormone activity
Weight management
Reduced FG
Reduced GT
Reduced HbA1c
Acute pancreatitis
SGL2iInhibition of SGLT2 in the kidneys
Increased urinary glucose excretion.
Reduction in blood glucose levels
Caloric loss and weight reduction.
Osmotic Diuresis.
Reduced FG,
Reduced GT
Reduced HbA1c
Urinary tract infection,
Genital infection
Lower limb amputation
MetforminEnhanced peripheral glucose uptake.
Inhibition of intestinal glucose transport.
Improvement of lipid metabolism.
Reduced FG,
Reduced GT
Reduced HbA1c
Vitamin B12 deficiency
Lactic acidosis
Table 2. Summary of Different Types of Intermittent Fasting Regimens and Their Positive and Adverse Effects on Metabolic Disorders.
Table 2. Summary of Different Types of Intermittent Fasting Regimens and Their Positive and Adverse Effects on Metabolic Disorders.
IF RegimenDescriptionPositive EffectsAdverse Effects
5:2 fasting diet
[4,119,129]
Involves a 5-day non-fasting period and a 2-day fasting period. Improvements in weight, HbA1c, lipids, fasting glucose, and quality of lifeFasting elevated the occurrence of hypoglycemia even with reduced medication.
Fasting may lead to over-compensation during non-fasting days.
Alternate day fasting
[110,111,130]
Involves alternating between a 24 h fasting period, during which individuals consume less than 25% of their usual energy needs, and a 24 h eating period, where they can eat normally.Decrease in body weight, waist circumference, systolic blood pressure, and fasting plasma glucose.Fatigue, Headaches
16 h:8 h TRF
[128,131]
Adhering to 16 h of abstinence from food and 8 h of food intake within 24 hHeightens insulin sensitivity and fat oxidation and decreases body weight, fat profile, and inflammationHunger and irritability, Palpitations, dizziness, headache, abdominal pain, mood changes, vomiting, and hypoglycemia
14 h:10 h TRF
[131,132,133]
Adhering to 14 h of abstinence from food and 10 h of food intake within 24 hReduced body weight, improved HbA1c, enhanced body composition, lowered blood pressure, and decreased lipids associated with cardiovascular disease.Disrupted Social Eating Patterns, Palpitations, dizziness, headache, abdominal pain, mood changes, vomiting, and hypoglycemia
Table 3. Summary of Different Types of Intermittent Fasting Regimens and Their Positive and Adverse Effects on Prediabetes.
Table 3. Summary of Different Types of Intermittent Fasting Regimens and Their Positive and Adverse Effects on Prediabetes.
IF RegimenDescriptionPositive EffectsAdverse Effects
5:2 fasting diet
[165,180].
Involves a 5-day non-fasting period and a 2-day fasting period. Improvements in body weight, HbA1c, lipids, fasting glucose, and appetite scoreIncreased hunger
Alternate-day fasting
[112,113,169]
Alternating 24 h fasting and 24 h eating periodImproved insulin sensitivity, decreased body weight, lower fasting insulin levels, improved IFG, reduced postprandial hyperglycemia, and decreased levels of HbA1cIncreased hunger, vomiting, redox imbalance, and glucose intolerance
Time-restricted feeding
[175,176]
Fasting and consuming meals within a limited timeframe of 24 h.Reduced FG, HbA1c, and postprandial glucoseDizziness, hunger, nausea
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Msane, S.; Khathi, A.; Sosibo, A. Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review. Nutrients 2024, 16, 2692. https://doi.org/10.3390/nu16162692

AMA Style

Msane S, Khathi A, Sosibo A. Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review. Nutrients. 2024; 16(16):2692. https://doi.org/10.3390/nu16162692

Chicago/Turabian Style

Msane, Sthembiso, Andile Khathi, and Aubrey Sosibo. 2024. "Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review" Nutrients 16, no. 16: 2692. https://doi.org/10.3390/nu16162692

APA Style

Msane, S., Khathi, A., & Sosibo, A. (2024). Therapeutic Potential of Various Intermittent Fasting Regimens in Alleviating Type 2 Diabetes Mellitus and Prediabetes: A Narrative Review. Nutrients, 16(16), 2692. https://doi.org/10.3390/nu16162692

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop